Abstract
Somatostatin (GHRIH) could be helpful in the treatment of diabetes mellitus when high levels of growth hormone and glucagon interfere with the metabolic control. In obese children the i.v. injection of 3 ug/kg of ideal body weight of GHRIH before i.v. glucose tolerance test lowered significantly the glucose disappearance rate, the plasma insulin levels, and delayed the peak value. In diabetic children the i.v. administration of 3 μg/kg of GHRIH over two min, followed by a 60 min infusion of 7 μg/kg in saline solution induced a significant decrease of blood sugar, growth hormone and glucagon levels; the administration of 3 μg/kg of CHRIH immediately before a standardized physical exertion significantly reduced the rise of growth hormone levels. GHRIH can open new possibilities in the treatment of juvenile diabetes, at least after puberty.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gargantini, L., Chiumello, G. EFFECTS OF SOMATOSTATIN ON PLASMA INSULIN, GROWTH HORMONE AND GLUCAGON LEVELS IN OBESE AND DIABETIC CHILDREN AND ADOLESCENTS. Pediatr Res 9, 669 (1975). https://doi.org/10.1203/00006450-197508000-00027
Issue Date:
DOI: https://doi.org/10.1203/00006450-197508000-00027